Cite
HARVARD Citation
Blumenschein, G. et al. (n.d.). 278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer. Journal for immunotherapy of cancer. pp. A169-A170. [Online].